Full CoverageTop news
Full lecanemab data presented at CTAD Alzheimer's Congress
As some hail new antibody treatment for Alzheimer's, safety and benefit questions persist
By Jennifer Couzin & Charles Piller
Brain shrinkage needs closer scrutiny in trials of anti-amyloid drugs
By Madhav Ramakrishna Thambisetty
All coverage
Experimental drug appears to slow progression of Alzheimer's
By Stephanie Stahl
Eisai makes the case for lecanemab after 2nd patient death
By Annalee Armstrong
New data shows Alzheimer's drug can slow cognitive decline
By Sony Salzman & Mary Kekatos
It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough
By Jonathan Schott
Focus: Rare success for Alzheimer's research unlocks hope for future therapies
By Julie Steenhuysen
Alzheimer's drug lecanemab hailed as momentous breakthrough
By James Gallagher
Experimental drug appears to slow progression of Alzheimer's disease in clinical trial but raises safety concerns
By Jacqueline Howard
Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus
By Deena Beasley
Alzheimer's drug lecanemab may slow losses in memory and thinking, study says : Shots - Health News
By Jon Hamilton
